MedWatch

Bavarian Nordic says more upgrades could be on the way

The biotech firm’s third upgrade in three weeks came hot on the heels of a recent contract with the US government. Should more orders follow, it could result in more upgrades, says Bavarian’s head of investor relations.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic raised its expectations for the full year on Friday last week, a consequence of the vaccine firm signing a contract with the US government concerning half a million doses of monkeypox vaccine Jynneos.

This is nothing short of the third guidance upgrade in the span of a few weeks that the firm has announced subsequent to landing a deal. However, despite now having a clearer view of upcoming orders, Bavarian has decided not to include expected orders into its prognosis, Head of Investor Relations at Bavarian Rolf Sass Sørensen tells MarketWire.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs